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Background:We report the ﬁndings of the SOURCE-ANZ registry of the clinical outcomes of the Edwards SAPIEN
™ Transcatheter Heart Valve (THV) in the Australian and New Zealand (ANZ) clinical environment.
Methods: This single arm registry of select patients treated in eight centres, represent the initial experiencewithin
ANZ with the balloon expandable Edwards SAPIEN THV delivered by transfemoral (TF) and transapical (TA) ac-
cess.
Results: The total enrolment for the study was 132 patients, 63 patients treated by TF, 56 by TA, and 2 patients
were withdrawn from the study. The mean ages: 83.7 (TF) and 81.7 (TA), female: 34.3% (TF) and 61.3% (TA), lo-
gistic EuroSCORE: 26.8% (TF) and 28.8% (TA), and with procedural success (successful implant without conver-
sion to surgery or death): 92.4% (TF) and 87.1% (TA) (p = 0.32). Outcomes were not signiﬁcantly different
between TF and TA implants. These included one year mortality of 13.6% (TF) and 21.7% (TA) (p = 0.24),
MACCE: 16.7% (TF) and 28.3% (TA) (p = 0.12), pacemaker: 4.6% (TF) and 8.3% (TA) (p = 0.39), and VARC
major vascular complication of 4.6% (TF) and 5.0% (TA) (p = 0.91).
Conclusion: TAVI in the ANZ clinical environment has demonstrated excellent outcomes for both the TA and TF
approaches in highly selected patients. These results are consistent with those demonstrated in European, Cana-
dian registries and the pivotal US clinical trials. ACTRN12611001026910.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. ds Lifesciences. DarrenWalters,
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We report the ﬁndings of the SOURCE-ANZ registry of the clinical
outcomes of the Edwards SAPIEN™ Transcatheter Heart Valve (THV)
(Edwards Lifesciences LLC, Irvine, CA, USA) for the treatment of severe
calciﬁc degenerative aortic stenosis out to one year in the Australian
and New Zealand clinical environment. Degenerative calciﬁc aortic ste-
nosis is the most common acquired valvular heart disease in developed
countries like United States, Europe, Australia and New Zealand. The in-
crease in the elderly population means that the prevalence of severe
aortic stenosis is expected to increase over time [1–3]. Currently it is es-
timated that around 4808 (2009–2010) surgical aortic valve replace-
ments (SAVR) are performed in Australia of which approximately
three quarters are bioprosthetic heart valves [4]. Open SAVR has been
the standard of care in the treatment of symptomatic aortic stenosis-ND license. 
407D.L. Walters et al. / International Journal of Cardiology 170 (2014) 406–412patients for patients eligible for surgery [5]. However between 25 and
50% of patients do not undergo surgery due to risk of surgery conferred
bymultiple co-morbidities such as advanced age, left ventricular systol-
ic dysfunction, coronary artery disease, renal failure and frailty [6–9].
Non-surgical alternatives including medical therapy and balloon aortic
valvuloplasty are associated with poor median survival among symp-
tomatic patients of approximately 18 months [10,11].
Transcatheter aortic valve implantation (TAVI) has been developed
over the last decade since the ﬁrst human implantation by Cribier
et al. in 2002 [12]. The technology may provide an option for the man-
agement of select high-risk patientswith symptomatic severe aortic ste-
nosis in whom the risk of SAVR is deemed prohibitive [13]. The United
States PARTNER trial of the Edwards SAPIEN THV has published out-
comes to two years [14–16]. This pivotal randomised controlled trial
compared both transfemoral (TF) and transapical (TA) valve implanta-
tion to SAVR in a high surgical risk cohort (Cohort A) [14]. A concurrent
arm of the study compared transfemoral TAVI to medical therapy in a
cohort declined for surgery (Cohort B) [15]. Transfemoral TAVI proved
superior tomedical therapy in Cohort B andwas non-inferior to surgery
for the primary end point of all-causemortality. Improvement in quality
of life measures and a favourable cost efﬁcacy proﬁle were noted in this
study for TAVI [17–19]. These ﬁndings are supported by the registry
data for both Edwards SAPIEN THV and the Medtronic CoreValve (Min-
neapolis, MN, USA) in predominantly elderly populations at high surgi-
cal risk [20–22].
Both the Edwards SAPIEN THV and the Medtronic CoreValve are
available for use in New Zealand however neither was approved by
the Therapeutic Goods Administration in Australia.
This single arm open label clinical trial describes the initial experi-
encewith both transfemoral and transapical implantation of the balloon
expandable Edwards SAPIEN THV system at eight centres in Australia
and New Zealand.
2. Methods
This clinical trial was a prospective multicentre single arm study of the safety and ef-
fectiveness of TAVI using the balloon expandable Edwards SAPIEN THV in high-risk pa-
tients with symptomatic severe aortic stenosis in Australia and New Zealand. The study
protocol was developed from the European SOURCE registry [20] and overseen by a mul-
tidisciplinary steering committee including cardiologists and cardiac surgeons from the
participating centres and approved by local ethics committees. The study was monitored
and deaths and other serious adverse events (SAEs) were independently adjudicated. All
patients signed a written informed consent before participating in this study and the
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki
(ACTRN12611001026910).
2.1. Registry
A total of eight centres participated in the study of the Edwards SAPIEN THV in
Australia and New Zealand. These sites represent the initial experience of the technology
prior to commercialisation in this region. The study was initiated in December 2008 and
the last patient was enrolled inDecember 2010. The registry represents 129 of the 220 pa-
tients who underwent Edwards SAPIEN TAVI in that time.
Other patients were implanted under special access or authorised prescriber schemes
operated by the Therapeutic Goods Administration in Australia. A list of site enrolments is
provided as Appendix 1. The original protocol mandated no minimum data monitoring.
This was increased to 30% on a subsequent revision. Anonymized data were collected
and used to generate the analyses for this registry.
2.2. Procedures and devices
The Edwards SAPIEN THV is a trileaﬂet bovine pericardial balloon expandable biolog-
ical heart valve. The device has been previously described [13]. Brieﬂy, the ThermaFix
processed valve leaﬂets are mounted on a stainless steel stent frame with the lower por-
tion of the frame covered with polyethylene terephthalate (PET) cloth. In this study the
valve was available in either 23 mm or 26 mm diameter with a stent height of 14.5 mm
and 16 mm respectively. The transfemoral system utilised the Retroﬂex delivery system
that was then replaced with the Retroﬂex 3 system with an integrated nose cone and
lower crossing proﬁle. TF access was achieved using 22 French (23 mm valve) and 24
French (26 mm valve) introducer sheaths. The Ascendra delivery system was used in
this study for TA access and has a 26 French introducer sheath. The valveswere implanted
using either the femoral or the transapical approach according to previously describedtechniques [13,23,24]. Transesophageal echocardiography was used to guide the
procedure.
2.3. Inclusion and exclusion criteria
Patients with severe symptomatic aortic stenosis (valve area b 0.8 cm2) with logistic
EuroSCORE≥20 whowere considered at high risk or inoperable for SAVRwere treated in
this study. When the EuroSCORE was less than 20 the patient could be enrolled if there
was consensus between the surgeon and cardiologists that the patient was at high risk
for open surgery for other reasons. These reasons included but were not limited to factors
such as cachexia/frailty, pulmonary insufﬁciency, home oxygen therapy, previous cardiac
surgery, porcelain aorta, pulmonary hypertension N60 mm Hg, recurrent pulmonary em-
bolus, right ventricular insufﬁciency, thoracic burning sequelae contraindicating open
chest surgery, history of mediastinum radiotherapy, severe connective tissue disease,
liver cirrhosis, and age N80 years.
All patients underwent clinical evaluation by a heart team consisting of at least two
cardiologists and one cardiac surgeon including echocardiography, coronary angiography,
aortography, femoral angiography and CT of the aorto-iliac vasculature. Patients were ex-
cluded if aortic annulus was b18 or N25 mm, the following criteria also excluded the pa-
tients from enrolment: Non-valvular aortic stenosis, congenital aortic stenosis, unicuspid
or bicuspid aortic valve, non-calciﬁc acquired aortic stenosis, evidence of intracardiac
mass, thrombus or vegetation, untreated clinically signiﬁcant coronary artery disease re-
quiring revascularization, severe deformation of the chest, severe coagulation problems,
active bacterial endocarditis or other active infections, myocardial infarction (MI) within
one month, unstable angina during index procedure, recent pulmonary emboli, recent
(within 6 months) cerebrovascular accident (CVA), patients unable to tolerate
anticoagulation therapy, signiﬁcant atheroma of femoral or iliac vessels— for TF approach,
severe tortuosities of the femoro-iliac vessels — for TF approach, femoro-iliac vessels
b7 mm— for TF approach, patientswith bilateral iliofemoral bypass— for TF approach, hy-
pertrophic cardiomyopathy with or without obstruction (HOCM), severe ventricular dys-
function with ejection fraction b20%, currently participating in an investigational drug or
another device trial that has not completed the primary endpoint or that clinically inter-
feres with the current trial endpoints.
2.4. Training and proctoring
Newsites underwent structured training andproctorship thatwas consistentwith the
global programme implemented by Edwards Lifesciences LLC, Irvine, California and previ-
ously described [20]. Proctors attended at least the ﬁrst four cases involving a new
institution.
2.5. Deﬁnitions and data collection
Patientswere assessed at baseline, discharge, 30 days and one year post TAVI. All data
was site reported, monitoredwith independent adjudication of serious adverse events. All
adverse events were reclassiﬁed according to VARC criteria [25] after these deﬁnitions be-
came available. There were no core laboratories. Data was managed by Flinders Clinical
Outcomes Research (Bedford Park, Australia). The data monitoring and adjudication was
performed by Paciﬁc Clinical Research Group (North Sydney, Australia). Complete one
year follow-up was available in 66 TF (98.5%) and 60 TA (96.8%) patients.
The primary outcome of the study was the safety and effectiveness of the Edwards
SAPIEN THV when used in TAVI measured by procedural success at 30 days. The second-
ary outcomewas the safety and effectiveness proﬁle of the therapy at one year. Procedural
success was deﬁned as device success (deployment of the valve, retrieval of the delivery
catheter, no conversion to open surgery and the patient leaving the interventional room
alive), no occurrence of in-hospital major adverse cardiac and cerebrovascular events
(MACCE) and ≤moderate aortic regurgitation (AR).
2.6. Echocardiographic data
Echocardiography was performed at baseline, one month and one year in a subset of
patients. The information was site reported and unblinded. There was no echocardiogra-
phy core laboratory for this study.
2.7. Statistical analysis
The statistical analysis was performed by Flinders Cardiovascular Outcomes Research
(Bedford Park, Australia) using STATA 12 data analysis and statistical software (StataCorp
LP, Texas, USA). Continuous variables are expressed as mean ± SD. Categorical variables
are given as frequencies and percentages. Dichotomous variables were compared with
Chi-square tests, while continuous variables were compared with Mann–Whitney U
tests. The survival analysis was performed using the Kaplan–Meier method, with patients
censored as of the last date known alive and followed to one year. As an exploratory anal-
ysis providing context for these results contrasted with the larger European experience,
30 day and 12 month outcomes for patients enrolled in the SOURCE ANZ and SOURCE
EU registries were compared using chi-square tests. A probability value of b0.05 is being
considered statistically signiﬁcant. The principal investigators had access to the reported
data and take responsibility for the data presented.
Table 2
Major complications at 30 days and 1 year.
Event 30 day TF
(n = 67)
1 year TF
(n = 66)
30 day TA
(n = 62)
1 year TA
(n = 60)
p-Value
(30 day)
p-Value
(1 year)
Death, n (%) 4 (5.97) 9 (13.64) 6 (9.67) 14 (23.33) 0.642 0.236
Stroke, n (%) 2 (2.99) 2 (3.03) 3 (4.84) 5 (8.33) 0.587 0.923
Myocardial
infarction,
n (%)
1 (1.49) 1 (1.52) 4 (6.45) 6 (10.0) 0.146 0.039
MACCE, n
(%)
7 (10.45) 11 (16.67) 10 (16.1) 17 (28.33) 0.342 0.117
Minor
vascular,
n (%)
7 (10.45) 7 (12.12) 1 (1.61) 1 (1.67) 0.038 0.023
Major
vascular,
n (%)
3 (4.48) 3 (4.55) 2 (3.22) 3 (5.00) 0.902 0.905
All vascular,
n (%)
10 (14.93) 10 (15.15) 3 (4.84) 4 (6.67) 0.094 0.132
Renal
failure, n
(%)
9 (13.43) 11 (16.67) 11 (17.74) 11 (18.33) 0.501 0.806
Permanent
pacemak-
er, n (%)
1 (1.49) 3 (4.55) 5 (8.06) 5 (8.33) 0.078 0.386
Comparison of baseline demographics of the ANZ SOURCE and SOURCE EU registries.
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3.1. Demographic and baseline characteristics
A total of approximately 312 patients were screened for a total en-
rolment of 132 patients consented to the study. Of these patients, 2 pa-
tientswerewithdrawn as they failed tomeet the screening and protocol
criteria due to inadequate femoral access. They did not continue on to
the procedure as determined by the proctor. One additional patient
crossed from the transfemoral arm to the transapical approach due to
failed femoral access and was analysed as treated. A THV was not im-
planted during the attempted transfemoral procedure.
A total of 129 patients then underwent TAVI with 63 patients (53%)
treated by the TF approach and 56 patients (47%) had the procedure un-
dertaken by TA access. Baseline demographics and risk factors are
displayed in Table 1.
The cohort selected for the transapical, compared to the
transfemoral approach, were more likely to be female (34.3% versus
61.3%, p = 0.002), have signiﬁcant peripheral vascular disease (25.4%
versus 53.2%, p = 0.001) or a porcelain aorta (3.0% versus 17.5%,
p = 0.006). These baseline differences in the groups indicate that pa-
tient related technical factors were signiﬁcant in determining the
heart teams' choice of the access route for the TAVI procedure. The
groups are different and outcomes should be compared with an under-
standing of these factors.Baseline
demographics
ANZ TF
(n = 67)
SOURCE TF
(n = 463)
20,26
ANZ TA
(n = 62)
SOURCE TA
(n = 575)20,26
Age (yrs) 83.7 81.7 81.7 80.7
Female 34.3% 55.2% 61.3% 56%
Logistic
EuroSCORE
26.8% 25.7% 28.8% 29.1%
Peripheral
vascular
disease
25.8% 10.9% 53.2% 27.5%
Carotid artery
stenosis
(N50%)
6.0% 7.6% 19.4% 17.1%3.2. Procedural parameters and outcomes
The procedural parameters and outcomes are summarised in
Table 1. The protocol deﬁned procedural success as device success
with no occurrence of in-hospital MACCE and ≤2 + AR. The TA and
TF success rates were similar with instances of conversion to surgery,
valve migration, valve malposition, coronary obstruction or signiﬁcant
AR isolated to a small number of cases in both arms of the registry
(Table 2).Table 1
Baseline demographics, procedural parameters and outcomes.
TF
(n = 67)
TA
(n = 62)
p-
Value
Baseline demographics
Age, mean (years ± SD) 83.70 81.69 0.16
Female, n (%) 23 (34.3) 38 (61.3) 0.002
Creatinine (mmol/l ± SD) 116.4 114.8 0.89
Logistic EuroSCORE, mean (±SD) 26.8 28.8% 0.57
Peripheral vascular disease, n (%) 17 (25.4) 33 (53.2) 0.001
Carotid artery stenosis (N50%), n (%) 4 (5.97) 12 (19.35) 0.02
Incidence of CAD, n (%) 54 (80.6) 46 (74.2) 0.39
Porcelain aorta, n (%) 2 (3.0) 11 (17.5) 0.006
Prior CABG, n (%) 27 (40.3) 25 (40.3) 1.0
Mitral valve disease, n (%) 16 (23.9) 18 (29.0) 0.51
NYHA (mean ± SD) 2.8 2.8 0.89
Procedural parameters and outcomes
Implanted valve size, mm
23 21 33
26 45 29
Acute procedural success (protocol deﬁned), n
(%)
62 (92.4) 54 (87.1) 0.321
Conversion to SAVR, n (%) 1 (1.49) 1 (1.61) 0.957
Aortic regurgitation N2+, n (%) 1 (1.49) 1 (1.61) 0.957
Valve migration, n (%) 1 (1.49) 2 (3.23) 0.518
Valve malposition, n (%) 0 1 (1.61) 0.298
Coronary obstruction, n (%) 1 (1.49) 1 (1.61) 0.957
TF = transfemoral, TA = transapical, SAVR = open surgical aortic valve replacement,
SD = standard deviation, CAD = coronary artery disease, CABG = coronary artery
bypass graft, NYHA = New York Heart Association functional classiﬁcation, technical
success = valve implanted, retrieval of delivery catheter, no conversion to open surgery
and patient leaves the room alive.
Incidence of
CAD
80.6% 47.4% 74.2% 56.0%
Porcelain aorta 3.00% 4.6% 17.5% 11.5%
Prior CABG 40.3% 17.6% 40.3% 26.9%
Comparison of 30 day complications of the ANZ SOURCE and SOURCE EU registries.
30 day event
rates (%)
TF
(n = 67)
TA (n = 62) ANZ total
(n = 129)
SOURCE EU
total*
(n = 1038)
Death 6.0 9.7 7.8 8.5
Stroke 3.0 4.8 3.9 2.5
Renal failure 13.4 17.7 15.5 8.7
Permanent
pacemaker
1.5 8.1 4.7 7.0
Vascular major 4.5 3.2 3.9 7.0
Vascular minor 10.5 1.6 6.2 5.5
Comparison of 1 year complications of the ANZ SOURCE and SOURCE EU registries.
1 year event
rates (%)
TF
(n = 66)
TA (n = 60) ANZ total
(n = 126)
SOURCE EU
total
(n = 1038)
20,26
Death 13.6 23.3 18.3 23.9
Stroke 3.0 3.3 3.2 4.5
Renal failure 16. 7 18.3 17.5 –
Permanent
pacemaker
4. 5 8.3 6.4 8.5
Vascular major 4. 5 5.0 4.8 12.3
Vascular minor 12.1 1. 7 7.1 –
TF = transfemoral, TA = transapical, MACCE = major adverse cardiac and
cerebrovascular events. ANZ versus SOURCE, p values are not signiﬁcant except for;
Baseline differences in peripheral vascular disease (p b 0.001), coronary artery disease
(p = 0.006) and prior CABG (p = 0.03); Complications of Renal Failure at 30 days,
Major Vascular at 1 year (p = 0.01).
Fig. 2. Kaplan–Meier curves of freedom from major adverse cardiac and cerebrovascular
events (MACCE) to 1 year.
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The major complications at 30 days and one year are shown in
Table 2. The overall mortality was 7.8% at 30 days and 18.3% at 1 year
(Fig. 1). The overall stroke ratewas 3.9% and 5.6% respectively. The over-
all MACCE was 13.2% (30 days) and 22.2% (1 year) (Fig. 2). Similarly,
the overall pacemaker rates were 4.7% (TF) and 6.3% (TA). The vascular
complications were classiﬁed according to VARC deﬁnitions and the
combined endpoint of major and minor vascular complications was
more likely to occur in the transfemoral approach.
3.4. Echocardiographic outcomes
The echocardiographic results at baseline, 30 days and one year are
summarised in Fig. 3. The outcomes for aortic regurgitation are
displayed in Fig. 4.
4. Discussion
The results from this study represent the initial experience within
Australia and New Zealand with the balloon expandable Edwards
SAPIEN THV. For highly selected patients with severe aortic stenosisFig. 1. The Kaplan–Meier curves of freedom frommortality for the total group (a) and by
approach (b).this technology represents a new therapeutic alternative for those
who are at high risk for SAVR or considered inoperable. The results of
the pivotal PARTNER trial, conducted predominantly in the USA in par-
allel to the SOURCE ANZ registry, have demonstrated for theﬁrst time in
a randomised trial that TAVI yields superior results to medical therapy
in patients with inoperable severe symptomatic aortic stenosis (hazard
ratio of 0.55, 95% conﬁdence interval of 0.40–0.74) [14–16]. In those
with a high surgical risk and treated with TAVI achieved outcomes not
inferior to SAVR at follow-up out to two years [16]. The technology is
now approved for selected patients by the FDA in the USA, in Europe
and a number of other countries including Canada. These results are
highly encouraging but the study enrolled only 12% of the patients ini-
tially screened for inclusion. The evaluation of such technologies and
procedures within the local health care environment is essential to en-
sure results are transferable and can be reasonably achieved within the
ANZ clinical arena. Our patient cohorts were similar in clinical risk pro-
ﬁle to those enrolled in the SOURCE EU registry [20,26]. They are com-
parable to a combination of patients enrolled in the PARTNER trial
Cohorts A and B. The comparison of the Australian SOURCE data with
that from SOURCE EU is displayed in Table 2. Our patients were more
likely to have peripheral vascular disease, coronary artery disease and
have had prior bypass surgery. In the TF arm, patients were more likely
to be male than in the SOURCE EU registry. Otherwise the groups were
of similar age and EuroSCORE. The deﬁnitions of procedural success
were a point of difference between the registrieswith the European reg-
istry deﬁning success as Edwards SAPIEN THV deployment, delivery
catheter retrieval, no conversion to SAVR, and the patient leaving the in-
terventional room alive [20,26]. The SOURCE ANZ registry procedural
success was deﬁned as the above plus no occurrence of in-hospital
MACCE and ≤2/4 AR. The difference in procedural success is related to
these deﬁnition differences. Hence death and major complications
rates at 30 days and one year are similar.
These results are also favourable in comparison of initial reports
from Canadian early experience where 30 day mortality was 11.3%
[21] However in TF group the 30 day mortality was 12.3% in ﬁrst half
of patients had decreased to 3.6% in the second half of their cohort. Sur-
vival at 12 months was better than SOURCE EU (81.7% vs 76.1%) [26].
This is again marginally better than the 12 month survival of the Cana-
dian group (74%) [21], PARTNER Cohort B (69.3%) [14], PARTNER Cohort
A (75.8%) [15] and the France 2 registry (76%) [22].
Vascular complications were observed in 4.8% of TF cases which is
again comparable in a favourable manner to 8% patients requiring
major vascular surgery in initial Canadian experience [21] and better
Fig. 3. Paired echo data to 1 year by approach. a) Transfemoral peak gradient (mm Hg), b) transapical peak gradient (mm Hg), c) transfemoral mean gradient (mm Hg), d) transapical
mean gradient (mm Hg), e) transfemoral ejection fraction (%), f) transapical ejection fraction (%).
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try [20,26]. These resultswere achieved using the22 and24 French fem-
oral delivery systems. Similar rates of major complications (4.1%) have
been observed with the lower proﬁle 18 French CoreValve system in
Australia and New Zealand [27]. The reassuring safety proﬁle in
SOURCE ANZ may be explained by careful patient selection, proctor
oversight and performance of the procedure at selected centres with
solid experience in structural intervention.
The rate of pacemaker implantation is similar to that previously re-
ported for the Edwards SAPIEN THV of 6.4% in this study at 12 months
and 8.5% in SOURCE EU [26], 5.4% in the Canadian group [13] and 4.5%
in PARTNER Cohort B [14] and 5.7% in PARTNER Cohort A [15].
The occurrence of aortic regurgitation (AR) and stroke following
TAVI represent signiﬁcant limitations for this technology, particularlyFig. 4. Paravalvular aortic regurgitatiowhen moving into intermediate risk groups is contemplated [28,29].
In our study 12 month echocardiographic data was available on 91 pa-
tients. Acute haemodynamic improvements were seen with the SAPIEN
THV and these were sustained at 30 days and one year. In terms of AR,
there were a small number of patients with more than mild AR report-
ed. AR of at least moderate severity has been associated with adverse
mortality outcomes at medium term (2 year) follow-up [30]. The inci-
dence of stroke in our cohort was 3.9% at 30 days and did not change
at 1 year. This is comparable to the results in SOURCE EU being 4.5% at
one year [26]. Peri-procedural thromboembolic events are responsible
for bulk of these episodes. Similar stroke rates have been reported in
PARTNER study and other registries at between 3.8% and 5.0%
[14,15,22]. In the PARTNER study a risk of stroke persisted beyond the
implant procedure. It is unclear if this related to the nature of then on echocardiography to 1 year.
Site name + site number Investigator name PI/Sub-I
St Vincent's Sydney (201) Dr David Baron PI
St Vincent's Sydney Dr Paul Jansz Sub-I
St Vincent's Sydney Dr Paul Roy Sub-I
St Vincent's Sydney Dr Phillip Spratt Sub-I
St Vincent's Sydney Dr David Muller Sub-I
John Hunter Hospital (203) Dr Peter Fletcher PI
John Hunter Hospital Dr Suku Thambar PI
John Hunter Hospital Dr Greg Bellamy Sub-I
John Hunter Hospital Dr Allen James Sub-I
John Hunter Hospital Dr Peng Seah Sub-I
John Hunter Hospital Dr Taranpreet Singh Sub-I
Prince of Wales (204) Dr Nigel Jepson PI
Prince of Wales Dr Hugh Wolfenden Sub-I
Prince of Wales Dr Peter Grant Sub-I
Prince of Wales Dr Mark Pitney Sub-I
Royal North Shore Hosp (205) Dr Ravinay Bhindi PI
Royal North Shore Hosp Dr H Nojoumian Sub-I
Royal North Shore Hosp Dr Greg Nelson Sub-I
Royal North Shore Hosp Dr Manu Mather Sub-I
Royal North Shore Hosp Dr Peter Brady Sub-I
Royal North Shore Hosp Dr Alex Huang Sub-I
Prince Charles Hospital (401) Dr Darren Walters PI & CI
Prince Charles Hospital Dr Andrew Clarke Sub-I
Prince Charles Hospital Dr Peter Tesar Sub-I
Prince Charles Hospital Dr Trevor Fayers Sub-I
Prince Charles Hospital Dr Brendan Bell Sub-I
Prince Charles Hospital Dr Con Aroney Sub-I
Prince Charles Hospital Dr Karl Poon Sub-I
Prince Charles Hospital Dr Mahala Hudaverdi Sub- I
Prince Charles Hospital Dr Sushil Allen Luis Sub-I
Prince Charles Hospital Dr Kris Nowakowski Sub-I
Prince Charles Hospital Dr Alexander Incani Sub-I
Prince Charles Hospital Dr Chris Raffel Sub-I
Flinders Medical Centre (501) Dr Ajay Sinhal PI
Flinders Medical Centre Prof Derek Chew Sub-I
Flinders Medical Centre Dr Jayme Scott Bennetts Sub-I
Flinders Medical Centre Dr John Knight Sub-I
Royal Perth Hospital (601) Dr Gerald Yong PI
Royal Perth Hospital Dr Robert Larbalestier Sub-I
Royal Perth Hospital Dr Sharad Shetty Sub-I
Royal Perth Hospital Dr James Rankin Sub-I
Royal Perth Hospital Dr Xiao-Fang Xu Sub-I
Royal Perth Hospital Dr Richard Clugston Sub-I
Royal Perth Hospital Dr Michael Muhlman Sub-I
Royal Perth Hospital Dr Raj Kanna Sub-I
Waikato Hospital (901) Dr Sanjeevan Pasupati PI
Waikato Hospital Dr Raewyn Fisher Sub-I
Waikato Hospital Dr Gerry Devlin Sub-I
Waikato Hospital Adam El Gamel Sub-I
Waikato Hospital Shaun Galvin Sub-I
Waikato Hospital Dr Nand Kerjirwal Sub-I
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the prosthesis itself or the stainless steel frame. Late strokes (N30 days)
were not seen in our study.
This study is not a randomised trial and patients were carefully se-
lected to receive a THV device by an approach based on technical and
clinical features that explain the observed baseline differences between
the two groups. TA patients weremore likely to be female patients with
small femoral anatomy, peripheral vascular disease or porcelain aorta
(Table 1). Despite these differences, the TA results for mortality at
30 day and one year were not signiﬁcantly different from those
achieved by the TF approach in this registry (Table 2). There was a not
a statistically signiﬁcant reduction in MACCE in the TF arm compared
to the transapical approach (16.7% versus 23.3% at 1 year, p = 0.09).
The difference in myocardial infarction or injury observed is probably
a function of the apical injury induced to the myocardium during this
approach (1.5% versus 10.0% at 1 year, p = 0.04). These innovative
technologies continue to evolve with iterations of the device aimed at
improving the ease of device introduction and accuracy of placement
and reducing complications associated with the procedure. Several
key issues have not been addressed in this study. Firstly, careful eco-
nomic evaluation of this procedurewithin the local clinical context is es-
sential to deﬁne the true value of this novel technology. Understanding
the costs associated with increased use of this therapeutic alternative,
and the gains in survival and quality of life will be essential in develop-
ing an economic rationale for providing this therapy in patientswith ad-
vanced age and limitations in functional capacity. Quality of life and cost
efﬁcacy analysis from the PARTNER study suggest the technology
should perform well in ANZ on these measures [17–19]. Secondly, as
the clinical data evolve, it is also anticipated that consideration of TAVI
will be undertaken for patients in with lower clinical risk than those
studied in these initial trials. The next generation of clinical trials are
seeking to target intermediate risk patients with STS scores of ≥4 com-
pared to the EuroSCOREs of≥20 and STS of≥10 required in early expe-
riences [29]. An additional limitation is the lack of a detailed screening
log across all sites such that the total number of patients screened
may have been underestimated.
5. Conclusion
The clinical introduction of TAVIwith the Edwards SAPIEN THV in the
ANZ clinical environment, in a select high risk cohort of patients has
demonstrated excellent outcomes for both the TA and TF approaches.
The results are consistentwith those demonstrated in European, Canadi-
an registries and the pivotal US clinical trials. Results with this technique
are reproducible in the short and medium term in high risk populations
with severe aortic stenosis. Signiﬁcant limitations do persist in terms of
procedural complications related to vascular injury and stroke. Addition-
al long-term data will be required in the ANZ region along with studies
on cost efﬁcacy andquality of life. This is particularly important as clinical
trials move to intermediate risk patient cohorts.Hospital name (city, country) n
Flinders Medical Centre (Adelaide, AU) 38
St. Vincent's Hospital (Sydney, AU) 22
Prince Charles Hospital (Brisbane, AU) 20
Waikato Hospital (Waikato, NZ) 17
John Hunter (Newcastle, AU) 11
Royal Perth Hospital (Perth, AU) 11
Prince Of Wales (Sydney, AU) 8
Royal North Shore (Sydney, AU) 5
Total 132
Appendix 1. Participating centres and patient enrolmentAU = Australia, NZ = New Zealand.
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